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Objectives This study sought to determine the prognostic value of B-type natriuretic peptide (BNP) in patients with heart failure with
preserved ejection fraction (HFPEF), in comparison to data in HF patients with reduced left ventricular (LV) EF (40%).
Background Management of patients with HFPEF is difficult. BNP is a useful biomarker in patients with reduced LVEF, but
data in HFPEF are scarce.
Methods In this study, 615 patients with mild to moderate HF (mean age 70 years, LVEF 33%) were followed for 18
months. BNP concentrations were measured at baseline and were related to the primary outcome, that is, a
composite of all-cause mortality and HF hospitalization, and to mortality alone. The population was divided in
quintiles, according to LVEF, and patients with reduced LVEF were compared with those with HFPEF.
Results There were 257 patients (42%) who had a primary endpoint and 171 (28%) who died. BNP levels were significantly higher
in patients with reduced LVEF than in those with HFPEF (p 0.001). BNP was a strong predictor of outcome, but LVEF was
not. Importantly, if similar levels of BNP were compared across the whole spectrum of LVEF, and for different cutoff levels
of LVEF, the associated risk of adverse outcome was similar in HFPEF patients as in those with reduced LVEF.
Conclusions BNP levels are lower in patients with HFPEF than in patients with HF with reduced LVEF, but for a given BNP
level, the prognosis in patients with HFPEF is as poor as in those with reduced LVEF. (J Am Coll Cardiol 2013;
61:1498–506) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.12.044o
rHeart failure with preserved ejection fraction (HFPEF) is
an increasingly large medical and epidemiological problem
(1–5). Although older studies reported that HFPEF pa-
tients in general had a better prognosis than HF patients
with a reduced left ventricular ejection fraction (LVEF) (6),
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2012, accepted December 17, 2012.more recent data indicate that mortality in HFPEF patients
is in fact similar (3,4). Whereas survival has improved over
the last 10 to 20 years in HF patients with reduced LVEF,
no change was observed in HFPEF patients.
See page 1507
A large number of trials have been conducted in HF patients
and reduced LVEF patients, examining angiotensin-
converting enzyme (ACE) inhibitors, beta-blockers, angioten-
sin receptor blockers (ARBs), and aldosterone receptor block-
ers (1,7). These trials reported significant improvements in
outcome, leading to strong recommendations for these drugs in
current HF guidelines. In contrast, relatively few studies have
been conducted in HFPEF. Although a recent meta-analysis
showed that medical treatment may improve exercise capacity
(8), none of the treatments was convincingly shown to improve
utcome, and therefore none of these drugs has received a
ecommendation for HFPEF in current HF guidelines (1,5,7).
Methodological issues may play a role in the disappoint-
ng results from trials in HFPEF: most trials enrolled
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April 9, 2013:1498–506 BNP and Prognosis in Heart Failurepatients based on only a “preserved” LVEF combined with
rather “soft” criteria related to symptoms of HF, and a
considerable proportion of them may not have had HF (5).
Comorbidities are common in HFPEF (9), and symptoms
of HF such as dyspnea and fatigue are aspecific and may be
secondary to other diseases such as anemia, obesity, and
chronic obstructive pulmonary disease (COPD) (10,11). One
way to overcome this problem is to employ strict echocardio-
graphic criteria (7,12), but there are many different definitions,
and measurement of these parameters is difficult and often not
very useful for daily practice (5).
Another approach to define the presence of HF in
patients with HFPEF is to use natriuretic peptides: B-type
natriuretic peptide (BNP); or N-terminal pro–B-type natri-
uretic peptide (NT-proBNP). These biomarkers are now
used on a large scale (13) and have been proven to be of
value in the management of HF patients with reduced
LVEF. Recent work has shown that these natriuretic
peptides may also be used in HFPEF, both for diagnostic
and for prognostic purposes (13–16).
The aim of the present study was therefore to study BNP
concentrations in a HF cohort of patients that included a
wide range of LVEF. By using BNP to grade the severity of
HF, we were able to compare the prognostic value of similar
levels of these peptides across the whole range of LVEF; in
other words, we were able to examine the prognostic value
of specific values of BNP across this range.
Methods
Patients. All patients in the present study participated in the
COACH (Coordinating Study Evaluating Outcomes of Advis-
ing and Counseling in Heart Failure) (ISRCNT98675639.)
(17,18). COACH was a randomized trial to evaluate the
effect of 2 levels of a disease management program (basic
support and intensive support) versus care as usual.
COACH showed no significant differences between the
groups. Patients were randomized before discharge, at the
end of a hospitalization for HF, when they were clinically
stable. BNP measurements were taken at this time.
Patients had to be 18 years of age, had to be in New
ork Heart Association (NYHA) functional classes II to
V, and had to have evidence of underlying structural heart
isease. The primary outcome was a composite of hospital-
zation for HF or all-cause mortality. A total of 1,023
atients were included in the main study, and follow-up was
erformed at 1, 3, 6, 12, and 18 months after discharge.
ospitalization for HF was defined as an unplanned over-
ight stay in a hospital (different dates for admission and
ischarge) as a result of progression of HF or directly related
o HF. All events were adjudicated by an independent
ndpoint committee. Of the 17 participating centers in
OACH, all but 1 agreed to collect additional blood
amples. The study followed the principles outlined in the
eclaration of Helsinki. Ethical approval, both for the maintudy and for the present substudy, was obtained from the Tedical Ethics Committee of the
niversity Medical Center, Gro-
ingen, and the other participating
ospitals, and all subjects gave
heir written informed consent.
easurement of BNP. Plasma
NP concentrations were mea-
ured as described in detail else-
here (19). In short, plasma
NP was measured using a flu-
rescence immunoassay kit (Tri-
ge, Biosite Incorporated, San
iego, California) and the mea-
urable range of BNP assays was
.0 to 5,000 pg/ml. To convert
NP to picomoles per liter, di-
ide by 3.47.
tatistical analysis. Data are
iven as mean  SD when nor-
ally distributed, as median and
nterquartile range when distrib-
ted not normally or skewed, and
s frequencies and percentages
or categorical variables. Associations between baseline vari-
bles were evaluated by means of 1-way analysis of variance,
he Kruskal-Wallis test, and chi-square or Fisher exact tests,
hen appropriate. LVEF was divided into 5 categories
20%, 21% to 30%, 31% to 40%, 41% to 50%, 51%) to
ssess relationships between baseline characteristics and
VEF. The prevalences of BNP are presented in categories
or descriptive purposes but in the analyses were used as
ontinuous variables.
To evaluate the association between BNP and the risk of
ll-cause mortality and hospitalization for worsening HF
efined as time to first event, we calculated unadjusted, age-
nd sex-adjusted, and multivariably adjusted hazard ratios
HRs), and 95% confidence intervals (CIs) using Cox
roportional hazards regression models.
In multivariable models, we mutually adjusted relevant
redictors of cardiovascular mortality and morbidity. These
ariables, in the order of strength of association with the risk
f all-cause mortality and hospitalization for worsening HF,
ere: history of cerebrovascular accident (stroke); estimated
lomerular filtration rate; previous hospitalization for HF;
ge; serum sodium, diabetes; NYHA functional class;
VEF; use of diuretics; use of beta-blockers; COPD; (history
f) hypertension; body mass index; atrial fibrillation/flutter; use
f ACE inhibitors and/or ARB; history of myocardial infarc-
ion; underlying heart disease; depressive symptoms; and dia-
tolic and systolic blood pressure. Depressive symptoms were
ssessed using the Centre for Epidemiological Studies Depres-
ion Scale, and a score 16 is considered as having depressive
ymptoms (20).
Initially, we assumed that the effect of BNP was mono-
onic, which is true for many risk/exposure relationships.
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
ARB  angiotensin
receptor blocker
BNP  B-type natriuretic
peptide
CI  confidence interval
COPD  chronic
obstructive pulmonary
disease
HFPEF  heart failure with
preserved ejection fraction
HR  hazard ratio
LVEF  left ventricular
ejection fraction
NT-proBNP  N-terminal
pro–B-type natriuretic
peptide
NYHA  New York Heart
Associationhe natural starting point, the straight-line model is often
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BNP and Prognosis in Heart Failure April 9, 2013:1498–506adequate, but other models must be investigated for possible
improvements in fit. We looked for nonlinearity by fitting a
first-order polynomial to the data (21). The best power
transformation xp was found, with the power p chosen from
he candidates 2, 1, 0.5, 0, 0.5, 1, 2, and 3, where x0
denotes log x. The set includes the straight-line (i.e., no
transformation) p  1, and the reciprocal, the square root
and square transformations. The best fitting power was p 
0 (logarithmic transformation). BNP showed a log-linear
functional shape with the response variables and was trans-
formed to a 2-log scale. This means that risk estimates
should be interpreted as the relative risk if values of BNP
were doubled (e.g., from 10 to 20 pg/ml). In the multivari-
able models, we additionally examined whether LVEF modi-
fied the effect of BNP on all-cause mortality and hospitaliza-
tion for worsening HF by including an interaction term. In a
sensitivity analysis, we also analyzed the robustness of the
predictive value of BNP in relation to LVEF by dichotomizing
LVEF in 40%, 45%, and 50% groups. The risk estimates of the
adjusted analyses were graphically presented for increasing
LVEF with different levels of BNP. For reference, BNP
concentrations of 250 and 750 pg/ml were chosen (based on
values in the 2008 HF guidelines [22]) conditionally on a
LVEF of 40%. The risk estimate curves were constructed using
the medians of these 3 BNP groups (0 to 250 pg/ml, 251 to
750 pg/ml, and 750 pg/ml).
The assumption of proportionality of hazards was
hecked by means of Schoenfeld residuals, using procedure
stphtest” in STATA (StataCorp, College Station, Texas),
hich is based on the methods described by Grambsch and
herneau (23). No severe deviations from parallelism were
vident. The assumption of linearity was checked graphi-
ally by studying the smoothed marginal residuals from the
ull model plotted against the covariate variables. The
inearity assumptions were satisfied.
Statistical analyses were performed using SPSS (version
6.0, SPSS Inc., Chicago, Illinois) and STATA (version
1.0). A 2-sided p value 0.05 was considered to be
ignificant.
esults
tudy population. There were 615 HF patients in whom
LVEF and BNP measurements at baseline were available
(Table 1). Baseline characteristics of this population of 615
patients were generally comparable to those of the complete
COACH cohort (n  1,023), although there are a few
small differences (Online Table 1). First, patients in the
entire COACH population overall had a slightly better
functional class than in the present population: 51% versus
48% NYHA class II; and 49% versus 52% NYHA class
III/IV, respectively, p  0.017. Second, hemoglobin levels
were slightly lower (12.6 vs. 12.8 g/dl, p  0.031).
BNP baseline measurements were available, respectively,
in 132 patients with LVEF 20%, in 199 patients with
LVEF 21% to 30%, in 129 patients with LVEF 31% to B40%, in 81 patients with LVEF 41% to 50%, and in 74
patients with LVEF 50%. Of the 615 LVEF measure-
ments in the current study, 523 (85%) were measured by
echocardiography; 88 (14%) were measured by radionuclide
imaging; and 4 (1%) were measured during angiography.
There were 180 patients in the group BNP 0 to 250 pg/ml,
238 patients in the group of BNP 251 to 750 pg/ml, and
197 patients in the group BNP 750 pg/ml. Median BNP
values in these 3 groups were 135 pg/ml, 450 pg/ml, and
1,260 pg/ml, respectively.
Association between LVEF, clinical characteristics, and
BNP. Patients with higher LVEF were older, more often
female, and they had a higher systolic blood pressure (Table 1).
Body mass index was also higher, and hemoglobin levels
were lower in patients with higher LVEF. The prevalence
of obesity, (history of) hypertension, and anemia all in-
creased in patients with higher LVEF (all p  0.05),
whereas a trend for more COPD was observed (p  0.05).
The frequency of depression, diabetes, and (history of)
stroke did not differ between the groups.
Use of HF medication was different for ACE inhibitors
and beta-blockers, and these drugs were less often used in
those with higher LVEF. Median levels of both BNP
decreased as LVEF increased (both p  0.001 for trend).
Distribution of the levels of natriuretic peptides in the 5
LVEF groups is shown in Figure 1. In the higher LVEF
groups, there were a higher proportion of patients with low
BNP, whereas in the lower LVEF groups most patients
were in the highest BNP group.
Association between BNP and outcome. During the
18-month study, the primary endpoint (all-cause mortality
and HF hospitalization) occurred in 257 patients (42%), and
171 of the 615 (28%) patients died. Follow-up was 100%
complete, and no patients were lost.
LVEF was not associated with the primary composite
endpoint and there were no significant differences between
the 5 LVEF groups (Fig. 2). The highest incidence of the
primary endpoint was 51% in patients with LVEF 41% to
50%, and the lowest incidence was 33% in patients with
LVEF 31% to 40%. LVEF was also not associated with
all-cause mortality alone and varied from 22% in patients
with LVEF 31% to 40% to 33% in those with LVEF 41%
to 50%.
BNP was a strong predictor for outcome (Fig. 2), both in
the whole population, as well as in the 2 subgroups of patients
with LVEF 40% and in those with LVEF 40%. Figure 3
shows the Kaplan-Meier survival curves for the composite
primary endpoint for BNP, for all patients (Fig. 3A), for
patients with LVEF 40% (Fig. 3B), and for patients with
VEF 40% (Fig. 3C). The association between BNP was
lso examined for all-cause mortality alone in the 3 LVEF
roups (Figs. 4A to 4C). BNP remained an independent
rognostic predictor after adjustment for LVEF (expressed
ontinuously or dichotomized using different LVEF cutoff
alues) and in the mutually adjusted analyses. Doubling of
NP was associated with a statistically significant 1.3-fold risk
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April 9, 2013:1498–506 BNP and Prognosis in Heart Failureof the composite of all-cause mortality and HF hospitalization
(p 0.001) (Table 2), and a 1.4-fold increased risk of all-cause
ortality alone (p  0.001) (Table 2). Introducing LVEF
ontinuously or dichotomized using different cutoff values
ardly changed the point estimates and confidence intervals of
he hazard rates of BNP.
When we determined risk estimates of LVEF on outcome
cross the whole spectrum of LVEF for several specific BNP
Fig. 5), there were no statistically significant changes in the
rognostic value of BNP with increasing LVEF, neither for the
rimary composite endpoint of all-cause mortality and HF hos-
italization (Fig. 5A) nor for all-cause mortality alone (Fig. 5B).
or the composite primary endpoint, the hazard ratio for
Baseline Characteristics of the Study PopulationTable 1 Baseline Characteristics of the Study Population
All Patients
(N  615)
LVEF
<20%
(n  132)
L
21
(n 
Age, yrs 70 12 67 12 7
Female 38 32
NYHA functional class
II 48 44
III/IV 52 56
LVEF, mean 33 16
Heart rate, beats/min 74 14 76 14 7
Systolic BP, mm Hg 118 21 111 19 11
Diastolic BP, mm Hg 69 12 68 11 6
BMI, kg/m2 27 5 25 5 2
Hemoglobin, g/l 12.8 1.9 13.4 1.8 12.
Sodium, mEq/l 139 4 139 4 13
eGFR, ml/min/1.73 m2 56 22 58 19 5
Natriuretic peptides
BNP, pg/ml 463 (212–918) 534 (275–1130) 502 (2
Medical history
Previous HF-hospitalization 34 23
Primary cause of HF
Ischemic 42 38
Nonischemic 58 62
Comorbidities
Atrial fibrillation/flutter* 36 31
Obesity† 22 14
Diabetes 27 20
Hypertension 42 31
Stroke 10 11
COPD 26 21
Anemia 38 26
Depressive symptoms‡ 39 42
Medication
ACE-I 74 78
ARB 12 13
ACE-I and/or ARB 84 89
Beta-blocker 66 79
Diuretic 97 97
Digoxin 32 33
Values are mean SD, %, or median (interquartile range). *Atrial fibrillation/flutter on baseline ec
epression Scale in which of 16 was used to define depressive symptoms (17).
ACE-I  angiotensin-converting enzyme inhibitor; ARB  angiotensin receptor blocker; BMI 
pulmonary disease; eGFR  estimated glomerular filtration rate; HF  heart failure; LVEF  leftpecific BNP values slightly increased with higher LVEF, lbut this was not statistically significant (HR: 1.00 [95% CI:
1.00 to 1.02], p  0.178), whereas for mortality alone it
remained the same (HR: 1.00 [95% CI: 0.99 to 1.02], p 
.512). Subsequent interaction analyses did not show any
tatistically significant interaction between LVEF and BNP.
he additional sensitivity analyses showed similar results.
imilar findings were also observed when the dataset was
imited to patients without atrial fibrillation or flutter.
iscussion
atients with HFPEF overall have lower levels of BNP than
o HF patients with reduced LVEF, but for a given BNP
)
LVEF
31%–40%
(n  129)
LVEF
41%–50%
(n  81)
LVEF
>50%
(n  74)
p Value
for Trend
71 11 75 10 73 11 0.001
35 41 55 0.002
0.029
43 53 60
57 47 40
36 47 59
77 16 71 11 72 13 0.031
122 22 124 22 124 22 0.001
71 15 69 14 68 11 0.719
27 6 26 5 28 6 0.001
9 12.7 2.1 12.5 1.9 12.1 2.0 0.001
139 5 139 4 138 4 0.503
57 24 51 19 54 20 0.044
20) 447 (215–798) 424 (179–828) 256 (112–598) 0.001
40 35 41 0.010
44 49 34 0.828
56 51 66
39 48 41 0.010
23 26 33 0.002
23 25 30 0.599
45 52 49 0.001
8 16 8 0.920
25 22 39 0.050
40 42 49 0.007
39 48 39 0.296
76 59 64 0.001
7 16 14 0.693
83 74 74 0.001
61 58 50 0.001
95 95 97 0.606
33 35 34 0.652
ogram. †Obesity defined as BMI30 kg/m2. ‡Assessed by the Centre for Epidemiological Studies
ass index; BNP  B-type natriuretic peptide; BP  blood pressure; COPD  chronic obstructive
lar ejection fraction; NYHA  New York Heart Association.VEF
%–30%
199
0 12
37
47
53
27
5 12
5 19
8 12
6 5
9 1.
8 4
5 23
43–11
33
42
58
31
21
34
40
10
28
35
34
79
11
88
68
98
31
hocardievel, the associated risk of all-cause mortality and HF
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BNP and Prognosis in Heart Failure April 9, 2013:1498–506hospitalization is at least as high in patients with HFPEF as
it is in those with low LVEF. This finding may have
important clinical implications. Indeed, the data suggest
that when the prognosis of HF patients is assessed, BNP
can and should be used, irrespective of LVEF. In addition,
Figure 1 Distribution of Patients
in the 5 LVEF Groups for BNP
The following divisions were made: low: 0 to 250 pg/ml; middle: 251 to 750
pg/ml; and high: 750 pg/ml. The proportion is depicted in stacked bars.
BNP  B-type natriuretic peptide; LVEF  left ventricular ejection fraction.
Figure 2
Association Between LVEF and BNP,
and Risk of the (Composite) Primary
Endpoint of All-Cause Death and HF Hospitalization
For LVEF, the population is grouped in percentages and for BNP in quintiles.
Risk on the y axis is shown as hazard ratio  95% confidence intervals using
the multivariate proportional hazards regression model. HF  heart failure;
other abbreviations as in Figure 1.Figure 3 BNP and Primary Endpoint (Death and
HF Hospitalization) in LVEF <40% and >40%
Kaplan-Meier survival curves of the association between BNP and the primary
endpoint (death and HF hospitalizations) in the whole population (A), in
patients with LVEF 40% (B), and in patients with LVEF 40% (C). Abbrevia-
tions as in Figures 1 and 2.
1503JACC Vol. 61, No. 14, 2013 van Veldhuisen et al.
April 9, 2013:1498–506 BNP and Prognosis in Heart Failureif populations of patients with HFPEF are examined, for
example to investigate the value of a new drug or device, a
(minimal) BNP level may be used to ensure a representative
HF population, that may benefit from treatment.
In the present study, BNP levels were overall lower in patients
with HFPEF than in HF patients with reduced LVEF, a finding
that has been reported before, both in acute (24) and chronic HF
(25). Patients with HFPEF, however, more often had obesity and
anemia, and COPD tended to be more frequent. Interestingly, all
these 3 conditions have been reported to mimic HF (10,11), and
it can be speculated that in some patients in the higher LVEF
groups, who were assumed to have HF, their complaints may have
been due to these other conditions. Indeed, in many of such
patients, BNP levels will most likely be normal or only moderately
elevated.
Despite the fact that BNP levels were overall lower in the
present study in patients with HFPEF than in those with
reduced LVEF, the associated risk for reaching the primary
endpoint was at least similar for a given BNP level. The finding
that BNP is the primary driver of outcome, and that adding
LVEF has limited value in prognostication, has been reported
before in patients with acute HF (26) and in a recent
community study (27). The present results are in line with this
and suggest that this may also be true in patients with nonacute
(or chronic) HF. On an individual patient basis, natriuretic
peptides can also be used to predict outcome, when incorpo-
rated into a risk model (28). For a long time it has been
HR for Outcome According to Doubling of BNPTable 2 HR for Outcome According to Doubling of BNP
HR (95% CI) Z p Value
All-cause mortality and HF
hospitalization
BNP unadjusted 1.29 (1.19–1.41) 5.96 0.001
BNP mutually adjusted with
LVEF analyzed as a
continuous variable*
1.24 (1.13–1.38) 4.26 0.001
BNP mutually adjusted with
LVEF below and above 40%
1.25 (1.13–1.38) 4.33 0.001
BNP mutually adjusted with
LVEF below and above 45%
1.24 (1.13–1.37) 4.31 0.001
BNP mutually adjusted with
LVEF below and above 50%
1.25 (1.13–1.38) 4.28 0.001
All-cause mortality
BNP unadjusted 1.41 (1.27–1.58) 6.19 0.001
BNP mutually adjusted with
LVEF analyzed as a
continuous variable*
1.36 (1.20–1.54) 4.69 0.001
BNP mutually adjusted with
LVEF 40%
1.36 (1.20–1.55) 4.75 0.001
BNP mutually adjusted with
LVEF 45%
1.35 (1.19–1.54) 4.66 0.001
BNP mutually adjusted with
LVEF 50%
1.36 (1.20–1.55) 4.72 0.001
*Adjusted for the following: history of cerebrovascular accident (stroke); estimated glomerular
filtration rate; previous hospitalization for HF; diabetes; serum sodium; age; NYHA functional class;
sex; use of glycosides; atrial fibrillation/flutter; use of beta-blockers; use of diuretics; COPD; history
of hypertension; (history of) use of ACE inhibitors and/or angiotensin receptor blockers; heart rate;
underlying heart disease; body mass index; depressive symptoms; history of myocardial infarction;Figure 4 BNP and All-Cause Mortality in LVEF <40% and >40%
Kaplan-Meier survival curves of the association between BNP and the primary
endpoint (all-cause mortality) in the whole population (A), in patients with LVEF
40% (B), and in patients with LVEF 40% (C). Abbreviations as in Figures 1
and 2.systolic and diastolic blood pressure.
CI  confidence interval; HR  hazard ratio; other abbreviations as in Table 1.
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BNP and Prognosis in Heart Failure April 9, 2013:1498–506assumed that morbidity and mortality in HFPEF patients was
lower than in HF patients with reduced LVEF (6,29). The
present findings indicate, however, that first, for a given BNP
level, which would suggest a similar severity of HF, the
associated risk is the same, and this was true for patients with
low, intermediate, and high BNP levels. In other words, if
patients truly have HFPEF (confirmed by an elevated BNP
level), their prognosis is not better than for HF patients with
reduced LVEF. Second, it supports the notion, that (elevated)
BNP levels could be used as an (additional) inclusion in
HFPEF trials, as has been suggested elsewhere (13,16). By
using such criteria in HFPEF, patients who do not really have
Figure 5 Risk Estimates of LVEF on Outcome
Risk on the y axis is shown as hazard ratio, for the primary endpoint (death
and HF hospitalization) (A) and for all-cause mortality alone (B) for specific lev-
els of BNP. The same division in 3 BNP groups was used (low group: 0 to 250
pg/ml, median 135 pg/ml; middle group: 251 to 750 pg/ml, median 450
pg/ml; and high group: 750 pg/ml, median 1,260 pg/ml), and the curves
were constructed using these median values in the 3 groups. Abbreviations as
in Figures 1 and 2.HF can be excluded, thereby increasing the proportion of Bpatients with true HF (and a poorer prognosis), and the
likelihood of getting a positive result in trials assessing the
effect of HF treatment. In addition, the use of biomarkers such
as BNP (and NT-proBNP) to select HF patients for targeted
HF treatment is attractive, because they can be measured
relatively easily in everyday clinical practice, in contrast, for
example, to state-of-the-art echocardiographic measurements
to assess diastolic function (30).
HFPEF is a large medical problem, which is increasing in
prevalence in the Western world (2,4,31), but treatment for
these patients is difficult. Although potentially interesting
findings have been reported on the use of ACE inhibitors
(32), ARB (33), and beta-blockers (34), no prospective
randomized trial has shown a statistically significant bene-
ficial effect on outcome, and none of these agents is
recommended for HFPEF in current HF guidelines (1,35).
In the largest study of HFPEF so far, with the ARB
irbesartan (36), there was no effect whatsoever on the
primary composite outcome of mortality or cardiovascular
hospitalization, and median value of NT-proBNP was 341
pg/ml in that study (16). Somewhat unexpectedly, another
substudy of that trial (37) showed that irbesartan was
effective in patients with NT-proBNP below but not above
the median, which contrasts with the findings from 2 other
studies of HFPEF (32,38), in which the drug effects were
slightly (but not significantly) better in patients with
NT-proBNP levels above the median. Nevertheless, these
findings from the large substudy with irbesartan (37) are
intriguing. It cannot be excluded that activation of natriuretic
peptides in HFPEF may reflect a (partly) different pathophys-
iology than in HF patients with reduced LVEF and reflect, for
example, more cardiorenal dysfunction in HFPEF. Recently,
data from another trial in HFPEF with the angiotensin
receptor neprilysin inhibitor LCZ696 were published (38).
Importantly, in that study, baseline NT-proBNP was used as
an entry criterion (400 pg/ml), which resulted in mean levels
of around 800 pg/ml, and remarkably, change in NT-proBNP
was in fact the primary endpoint of that study.
Study limitations. First, the number of patients studied was
relatively small, particularly for those with HFPEF (LVEF
40%), and the number of patients with LVEF45% or even
50% was even smaller. We chose a LVEF of 40% for
ractical purposes, and because many other large trials used
his, but it may be argued that some of these patients do not
ave a (completely) preserved systolic function. Second, sys-
ematic echocardiographic evaluations to examine diastolic
ysfunction (preferably with the use of a core lab) were not
one. Although this would have been useful, BNP levels have
een shown to correlate with indices of diastolic dysfunction
39,40). Nevertheless, it must be noted, that the diagnostic
ccuracy of natriuretic peptides appears to be less in patients
ith HFPEF than in those with HF and reduced LVEF
24,41). Third, serial measurements of BNP would have been
nteresting to assess further the prognostic association between
NP and LVEF, but these were not available.
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For a given BNP level, the prognosis in patients with
HFPEF is similar as in those with reduced LVEF. These
findings may have important implications in the manage-
ment of HFPEF patients in everyday clinical practice and in
the design of trials in HFPEF.
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